Discovery of a new activator of Slack potassium channels with robust efficacy in models of histamine-independent and chronic itch
Balzulat, A.; Zhu, W. F.; Flauaus, C.; Hernandez-Olmos, V.; Heering, J.; Sethumadhavan, S.; Dubiel, M.; Frank, A.; Menge, A.; Hebchen, M.; Metzner, K.; Lu, R.; Lukowski, R.; Ruth, P.; Knapp, S.; Mueller, S.; Steinhilber, D.; Haenelt, I.; Stark, H.; Proschak, E.; Schmidtko, A.
10.1101/2023.10.05.560997 bioRxivShow abstract
Various disorders are accompanied by histamine-independent itching, which is often resistant to the currently available therapies. In this study, we hypothesized that pharmacological activation of Slack (Kcnt1, KNa1.1), a potassium channel highly expressed in itch-sensitive sensory neurons, has therapeutic potential for the treatment of itching. Based on the Slack-activating antipsychotic drug, loxapine, we designed a series of new derivatives with improved pharmacodynamic and pharmacokinetic profiles that enabled us to validate Slack as a pharmacological target in vivo. One of these new Slack activators, compound 6, exhibited negligible dopamine D2 and D3 receptor binding, unlike loxapine. We found that compound 6 displayed potent on-target antipruritic activity in multiple mouse models of acute histamine-independent and chronic itch without motor side effects. These properties make compound 6 a lead molecule for the development of new antipruritic therapies targeting Slack.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.